Vir Biotechnology CMO to Step Down April 24

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What leadership change did Vir Biotechnology (VIR) disclose?

When will Vir Biotechnology’s Chief Medical Officer step down?

What position is changing at Vir Biotechnology (VIR)?

Has Vir Biotechnology started searching for a new Chief Medical Officer?

Who is stepping down from an executive role at Vir Biotechnology?

Vir Biotechnology, Inc. reported a leadership change in its medical organization.

Accepted by SEC EDGAR 04/10/2026 - 04:01 PM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Vir Biotechnology, Inc. reported a leadership change in its medical organization. Executive Vice President and Chief Medical Officer Mark Eisner, MD, MPH has informed the company that he will step down from his role, effective April 24, 2026. The company has begun a search for a successor to oversee its clinical and medical strategy.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

CMO departure effective date: April 24, 2026 Notification date: April 7, 2026

2 metrics

CMO departure effective date April 24, 2026 Effective date Mark Eisner steps down as EVP and CMO

Notification date April 7, 2026 Date Mark Eisner informed the company of his decision

Executive Vice President, Chief Medical Officer, Nasdaq Global Select Market

3 terms

Executive Vice President financial

"Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer"

An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.

Chief Medical Officer financial

"Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc."

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Nasdaq Global Select Market financial

"VIR | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Vir Biotechnology disclosed that Executive Vice President and Chief Medical Officer Mark Eisner will step down effective April 24, 2026. He informed the company of his decision on April 7, 2026, and Vir has started searching for his replacement.

Vir Biotechnology’s Chief Medical Officer, Mark Eisner, will step down effective April 24, 2026. The decision was communicated to the company on April 7, 2026, giving time for transition planning and the initiation of a successor search.

The role of Executive Vice President and Chief Medical Officer at Vir Biotechnology is changing. Mark Eisner, MD, MPH, has notified the company that he will leave the position, effective April 24, 2026, prompting a formal search for a new CMO.

Yes, Vir Biotechnology has initiated a search for a new Chief Medical Officer. This follows the notification from current EVP and CMO Mark Eisner on April 7, 2026, that he will step down from the role effective April 24, 2026.

Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer, is stepping down from Vir Biotechnology. He informed the company on April 7, 2026, and his departure will be effective April 24, 2026, as the company seeks a successor.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 7, 2026

Vir Biotechnology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39083

81-2730369

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1800 Owens Street, Suite 900

San Francisco, California 94158

(Address of Principal Executive Offices, including Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, $0.0001 par value

VIR

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026. The Company has initiated a search for his successor.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

VIR BIOTECHNOLOGY, INC.

Date: April 10, 2026

/s/ Marianne De Backer

Marianne De Backer, M.Sc., Ph.D., MBA

President and Chief Executive Officer

3 documents